Key Takeaways
- • QIAGEN N.V. entered a Business Combination Agreement with Crown NL Bidco B.V., an EQT XI fund vehicle, under which the Bidder plans a voluntary public tender offer at EUR 46.50 per share in cash.
- • The transaction values QIAGEN at approximately EUR 10.8 billion (about USD 12.1 billion) in enterprise value, including roughly USD 1.1 billion of net debt.
- • The offer represents a 40.3% premium to QIAGEN's unaffected share price as of July 8, 2026, and a 46.9% premium to the three-month VWAP of EUR 31.66.
- • The QIAGEN Boards unanimously approved the agreement and will recommend that shareholders tender, subject to the offer document and fiduciary duties.
- • Closing is expected in mid-2027; QIAGEN suspended its full-year 2026 outlook and reported preliminary Q3 2026 net sales of USD 548 million and adjusted diluted EPS of USD 0.65.
Summary
QIAGEN N.V. (NYSE: QGEN; Frankfurt: QIA) announced on October 21, 2026 that it has entered into a Business Combination Agreement with Crown NL Bidco B.V. (the "Bidder"), a holding company indirectly controlled by the EQT XI fund ("EQT Private Equity"). Co-investors include Luxinva S.A., a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA), and CPP Investment Board Europe Inc., a wholly owned subsidiary of CPP Investments. EQT Private Equity is managed and controlled by affiliates of EQT AB, based in Stockholm.
The Bidder intends to launch a voluntary public tender offer for all QIAGEN shares at EUR 46.50 per share in cash. The company stated the transaction values QIAGEN at approximately EUR 10.8 billion in enterprise value (about USD 12.1 billion at current exchange rates), including approximately USD 1.1 billion of net debt. The offer represents a 40.3% premium to the unaffected share price as of July 8, 2026, the last trading day before market reports on private equity takeover interest, and a 46.9% premium to the three-month XETRA VWAP of EUR 31.66.
The transaction follows a review by the Supervisory and Managing Boards that included discussions with both strategic and financial parties. Both boards unanimously approved the agreement and intend to recommend that shareholders tender their shares and vote in favor of the resolutions at an Extraordinary General Meeting. The formal recommendation will follow publication of the offer document after clearance by BaFin and the filing of U.S. tender offer materials. QIAGEN will continue to operate under its name and brand, and EQT Private Equity has made commitments covering business continuity, key brands, operational footprint, R&D, employees, financing and culture.
Completion is subject to a 50% plus one share minimum acceptance threshold, approval of Post-Closing Measures at the EGM, a separate implementation decision by the boards, and merger control and foreign investment clearances. Under the agreement, the boards will implement the Post-Closing Measures if they receive at least 80% of votes cast at the EGM; otherwise they may still proceed if they judge it in QIAGEN's best interest and it has substantial shareholder support. Non-tendering shareholders would receive a cash distribution equal to the offer price less applicable withholding taxes, and the FSE and NYSE listings would be terminated. Closing is currently expected in mid-2027. If closing has not occurred within ten months, QIAGEN may pay an interim dividend of up to USD 0.47 per share, not deducted from the offer price.
Alongside the deal, QIAGEN disclosed preliminary third-quarter 2026 results, with net sales of USD 548 million at both reported and constant exchange rates and adjusted diluted EPS of USD 0.65. Because of the pending transaction, the company has suspended its full-year 2026 outlook.
The Bidder intends to launch a voluntary public tender offer for all QIAGEN shares at EUR 46.50 per share in cash. The company stated the transaction values QIAGEN at approximately EUR 10.8 billion in enterprise value (about USD 12.1 billion at current exchange rates), including approximately USD 1.1 billion of net debt. The offer represents a 40.3% premium to the unaffected share price as of July 8, 2026, the last trading day before market reports on private equity takeover interest, and a 46.9% premium to the three-month XETRA VWAP of EUR 31.66.
The transaction follows a review by the Supervisory and Managing Boards that included discussions with both strategic and financial parties. Both boards unanimously approved the agreement and intend to recommend that shareholders tender their shares and vote in favor of the resolutions at an Extraordinary General Meeting. The formal recommendation will follow publication of the offer document after clearance by BaFin and the filing of U.S. tender offer materials. QIAGEN will continue to operate under its name and brand, and EQT Private Equity has made commitments covering business continuity, key brands, operational footprint, R&D, employees, financing and culture.
Completion is subject to a 50% plus one share minimum acceptance threshold, approval of Post-Closing Measures at the EGM, a separate implementation decision by the boards, and merger control and foreign investment clearances. Under the agreement, the boards will implement the Post-Closing Measures if they receive at least 80% of votes cast at the EGM; otherwise they may still proceed if they judge it in QIAGEN's best interest and it has substantial shareholder support. Non-tendering shareholders would receive a cash distribution equal to the offer price less applicable withholding taxes, and the FSE and NYSE listings would be terminated. Closing is currently expected in mid-2027. If closing has not occurred within ten months, QIAGEN may pay an interim dividend of up to USD 0.47 per share, not deducted from the offer price.
Alongside the deal, QIAGEN disclosed preliminary third-quarter 2026 results, with net sales of USD 548 million at both reported and constant exchange rates and adjusted diluted EPS of USD 0.65. Because of the pending transaction, the company has suspended its full-year 2026 outlook.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.